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Background: Neuroinflammation regulates both disease pathogenesis and repair in multiple sclerosis. In early
multiple sclerosis lesion development, neuroinflammation causes demyelination and axonal injury, the likely final
common determinant of disability. Here we report the identification of a novel neuroinflammatory mediator,
Disabled-2 (Dab2). Dab2 is an intracellular adaptor protein with previously unknown function in the central nervous
system.
Results: We report that Dab2 is up-regulated in lesional macrophages/microglia in the spinal cord in murine
experimental autoimmune encephalomyelitis, a model of multiple sclerosis. We demonstrate that dab2 expression
is positively correlated with experimental autoimmune encephalomyelitis disease severity during the acute disease
phase. Furthermore, dab2-deficient mice have a less severe experimental autoimmune encephalomyelitis disease
course and suffer less neuroinflammation and less axonal injury than their wild-type littermates. We demonstrate
that dab2 expression is strongly associated with the expression of inducible nitric oxide synthase. We further
demonstrate that Dab2 is expressed at the protein level by macrophages in early acute human multiple sclerosis
lesions and that this correlates with axonal injury.
Conclusions: Together, these results suggest that endogenous Dab2 exacerbates central nervous system
inflammation, potentially acting to up-regulate reactive oxygen species expression in macrophages and microglia,
and that it is of potential pathogenic relevance in Multiple Sclerosis.
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Neuroinflammation regulates both disease pathogenesis
and repair in multiple sclerosis (MS). In acute MS le-
sions, neuroinflammation causes demyelination [1] and
axonal injury [2,3]. A better molecular understanding of
the MS-associated neuroinflammatory process is likely
to yield novel proteins and pathways that could enhance
our understanding of pathogenesis or yield novel thera-
peutic targets. Using a common animal model of MS,
experimental autoimmune encephalomyelitis (EAE), our* Correspondence: vilija.jokubaitis@unimelb.edu.au
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reproduction in any medium, provided the orlaboratory sought to identify genes that are differentially
expressed by glia in EAE relative to healthy mice, and
that could potentially regulate neuroinflammatory pro-
cesses. Using RNA microarray expression analysis we
identified Disabled-2 (Dab2) as being significantly up-
regulated in EAE and, based on extant literature, poten-
tially expressed by glia, and therefore chose this mol-
ecule for further study.
Disabled-2, a cytosolic adaptor protein, is part of a lar-
ger family of proteins comprising Drosophila Disabled
(Dab) and mammalian Disabled-1 (Dab1). Unlike Dab
and Dab1, which have neuronally-restricted expression
profiles [4,5], Dab2 is broadly expressed in the brain,
kidney, ovaries, breast and other organs [6-9]. There are
two predominant Dab2 splice variants encoding 96 kDral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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form is the predominant isoform found in the adult,
whereas, the p67 isoform is predominantly expressed
during embryogenesis [10]. Disabled-2 expression within
the visceral endoderm during embryonic development is
necessary for survival of the early embryo [8,10,11]. The
Dab-2 has also been shown to be involved in numerous
other biological functions, varying according to cell type,
cell cycle stage and developmental stage, including re-
ceptor endocytosis [10,12,13] and cell migration [8,14].
Additionally, Dab2 has previously been shown to be
up-regulated during various CNS injury responses. For
instance, a study of mechanical cryoinjury within the rat
frontal cortex reported the up-regulation of the p96
Dab2 isoform by macrophages and astrocytes within le-
sioned tissue [15]. Furthermore, it has previously been
reported that dab2 is up-regulated within human MS le-
sions, in a microarray analysis of autopsy specimens [6].
However, its role or function in this context remains to
be elucidated.
We show that dab2 expression is positively correlated
with EAE disease severity during the acute disease
phase, and that Dab2 is principally expressed by micro-
glia/macrophages and astrocytes within EAE lesions.
Using Dab2 knock-out mice, we demonstrate that,
in the absence of Dab2, EAE disease severity is amelio-
rated and that this correlates with a decrease in the ex-
pression of inducible nitric oxide synthase (iNOS) and
interleukin-1β (IL-1β). In Multiple Sclerosis, we show
that Dab2 is highly expressed in macrophages in the
early acute lesion, but that its expression is diminished
in late acute lesions and almost absent in chronic MS le-
sions. Together these data demonstrate that endogenous
Dab2 expression exacerbates EAE severity, and is of po-
tential relevance to MS pathology because its macro-
phage expression profile is associated with lesion acuity.
Results
Dab2 Expression is up-regulated in murine EAE spinal
cord
We initially sought to identify genes that could poten-
tially regulate neural cell survival or repair processes in
the context of inflammatory demyelination. Therefore, a
comparative analysis of gene expression was undertaken
in healthy control SJL/J mice and those subjected to
moderate EAE (clinical grade 2.5). Microarray analyses
revealed that dab2 mRNA expression was consistently
up-regulated in the disease state on average 3.5 fold
(p=2.05x10-3; supplementary data).
To independently confirm these microarray findings, we
assessed Dab2 gene and protein expression in C57B/6
mice during MOG-induced EAE. Quantitative PCR ana-
lysis revealed a strong, positive correlation between dab2
expression and EAE disease severity with a Spearman’srank co-efficient of 0.92, p<0.0001 (Figure 1a). In order to
determine whether this up-regulation of dab2 at the
mRNA level translated into an increase in Dab2 protein,
Western Blot analyses of relevant tissues were per-
formed. Analysis of tissue derived from healthy control
mice and mice with an EAE grade of 3.0 showed that
Dab2 was markedly up-regulated in the spinal cord and
hindbrain, but not forebrain of EAE mice, consistent
with the pattern of immune-mediated injury in this
EAE model. Notably, Dab2 expression was not detect-
able in the spleen of healthy control or EAE animals
(Figure 1b) indicating that Dab2 is not highly expressed
in lymphocytes or resting macrophages. Immunohisto-
chemistry was then performed on coronal sections of
spinal cord to characterize the pattern of Dab2 expres-
sion in health and disease. Concordant with the quanti-
tative PCR and Western Blot data, Dab2 expression
could not be detected in the spinal cords of healthy
mice (Figure 1c), however, Dab2 staining increased with
EAE disease severity, where it was most intense from
clinical grade 2.5. No Dab2 staining was detectable in
the normal appearing white matter (NAWM) of the
EAE spinal cord (Figure 1d). We found that Dab2 ex-
pression was predominantly interspersed throughout
inflammatory lesions (Figure 1e). Staining was most in-
tense in the core of inflammatory lesions, and tapered
off towards their edges.
To determine the cell specificity of Dab2 expression
within EAE lesions, dual epifluorescence immuno-
histochemical analyses were performed using confo-
cal microscopy. The Dab2 protein was predominantly
expressed by CD11b-positive macrophages/microglia
(Figure 2a) and GFAP-positive astrocytes (Figure 2b) as
well as a small sub-population of PLP-positive oligoden-
drocytes and NG2-positive oligodendrocyte progenitors
(Additional file 1: Figure S1). However, Dab2 was not
expressed by CD3-positive T-cells (Figure 2c); demonstrat-
ing that the up-regulation of Dab2 expression in the
C57B/6 EAE spinal cord is a macrophage/microglial and
macroglial cell response. Using primary cells derived from
early post-natal rats, we confirmed that dab2 and Dab2
are more highly expressed by microglia and astrocytes
than either oligodendrocytes or their progenitors in their
native state in vitro (Additional file 2: Figure S2).
Deletion of Dab2 expression reduces EAE severity
To ascertain the impact of Dab2 expression on the dis-
ease course of MOG-EAE, we induced the disease in
Dab2 wild-type, Dab2 heterozygote and Dab2 knockout
littermates [8]. The Dab2 wild-type and heterozygous
mice had a similar disease onset, however, EAE scores of
Dab2 heterozygous mice diverged from those of wild-
type littermate controls from 14 days post-immunization
and remained significantly reduced until experimental
Figure 1 Dab2 expression is up-regulated in the murine C57B/6 MOG-EAE model relative to health. a: Realtime PCR quantitation of dab2
gene expression in the spinal cords of MOG EAE-immunised mice was expressed relative to healthy controls. Analysis reveals that dab2 gene
expression is positively correlated with disease severity (HC: Healthy Control; Spearmann’s rank correlation r2=0.921, p<0.0001). b: Western blot
analysis of Dab2 expression in healthy control mice and those subjected to EAE (grade 3.0). 1. Healthy spinal cord 2. EAE spinal cord 3. Healthy
forebrain 4. EAE forebrain 5. Healthy hindbrain 6. EAE hindbrain 7. Healthy spleen 8. EAE spleen. Shown is a marked up-regulation of both the
p96 and p67 Dab2 isoforms in the EAE spinal cord and hindbrain. c/d/e: Scale bar represents 200μm c: Dab2 staining is undetectable in the
healthy spinal cord. d: A region of EAE spinal cord spared from inflammation shows no Dab2 staining. e: A region of EAE spinal cord containing
inflammatory infiltrates (DAPI-positive nuclear accumulation) shows Dab2 staining throughout the lesions.
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ease scores that significantly diverged from 12 days until
16 days post-immunization (Figure 3b). Both Dab2
heterozygote and Dab2 knockout mice displayed signifi-
cantly greater survival rates in response to EAE challenge
relative to Dab2 wild-type littermate controls (Chi-Square
test p<0.01, p<0.05 respectively; Figure 3c & 3d).
It has now been established that MOG-EAE features
high levels of lesional inflammatory axonal injury [16-18].
To determine the effect of Dab2 deletion on axonal injury,
serum was collected from mice at disease end-point and
analysed for phosphorylated neurofilament heavy chain
(pNF-H) concentration by ELISA. Analyses revealed that
both Dab2 heterozygote (Figure 3e) and Dab2 knockout
(Figure 3f) mice had significantly less pNF-H in their
serum (p<0.01 for both), and hence suffered less axonal
injury than their Dab2 wild-type littermates.
It has been demonstrated that Dab2 can regulate the
migration of various cell types both in vivo and in vitro
[8,14] thus raising the possibility that the EAE pheno-
type of Dab2 heterozygous and knockout mice could
be due to a recruitment block of macrophages into
the EAE spinal cord, and subsequently of macrophages/
microglia into inflammatory lesions. To examine this
possibility, we assessed the inflammatory infiltrates con-
tained within the spinal cords of Dab2 wild-type, hetero-
zygous and knockout EAE mice (Figure 4a-c). Therewere no significant differences in the average number of
inflammatory infiltrates within coronal sections of the
lumbar expansion of Dab2 wild-type, heterozygote or
knockout mice (24±2 lesions/section, 26±2 lesions/
section, 20±3 lesions/section respectively; Figure 4d).
However, the average size of lesions differed significantly
between genotypes (25,400 μm2 ± 2,300 μm2 wild-type;
8,200 μm2 ± 1,500 μm2 heterozygote; 2310μm2 ± 510 μm2
knockout; Figure 4e). Densitometry analyses of cell
types shown to express Dab2 (macrophages/microglia,
astrocytes and NG2 positive cells) were then performed to
further characterise the composition of EAE lesions. It
was found that Dab2 wild-type, Dab2 heterozygote and
Dab2 knockout lesions contained proportionally equi-
valent numbers of macrophages/microglia, astrocytes,
NG2 progenitors and other cell types, however, Dab2 het-
erozygote and knockout lesions were less cell dense overall
than lesions found in the spinal cords of Dab2 wild-type
mice (Figure 4f). Similarly, normal-appearing white matter
(NAWM) in Dab2-deficient mice was less cell-dense than
NAWM from wild-type mice, with no differences in cell-
type proportions (Additional file 3: Figure S3A). In con-
trast, cell density and cell-type proportions were equiva-
lent in healthy tissue derived from Dab2 wild-type, and
Dab2-deficient mice (Additional file 3: Figure S3B) arguing
that the observed EAE phenotype was not driven by differ-






















Figure 2 Characterization of Dab2 expression within the EAE
spinal cord. Immunoflourescent staining for Dab2 in the lumbar
expansion in an EAE grade 3.0 C57B/6 wild-type mouse spinal cord.
Representative confocal images show a: Dual epifluorescence image
showing that the vast majority of CD11b-positive macrophages/
microglia also stain positively for Dab2. Dab2-negative microglia
(arrowhead). b: Dual epifluoresence image showing that a large
proportion of GFAP-positive astrocytes also stain positively for Dab2
(arrows). c: Dual epifluoresence image showing that CD3-positive
T-lymphocytes do not express Dab2 within inflammatory infiltrates.
Scale bars represent 50 μm.
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T-cells
To exclude the possibility that EAE disease severity was
ameliorated in Dab2 deficient mice due to aberrant T-
cell priming or activation, passive transfer EAE experi-
ments were performed (Additional file 4: Figure S4). We
found that disease could be transferred from both Dab2
heterozygous and Dab2 knockout mice to Dab2 wild-
type recipient (C57B/6) mice. Disease was induced in 5/
5 wild-type recipients after transfer of T-cells from Dab2
knockout mice (EAE day 22 average grade 1.25; range
1–2.25) and in 3/3 wild-type recipients after transfer of
T-cells from Dab2 heterozygote mice (EAE day 22 aver-
age grade 1.17; range 1–1.5). These results collectively
suggest that the genetic deletion of Dab2 does not sig-
nificantly interfere with peripheral T-cell priming, activa-
tion or initial lesion formation.
Dab2 Gene expression is positively correlated with iNOS
and IL-1β gene expression in mice subjected to EAE
Given that Dab2-deficient mice did not display a macro-
phage recruitment deficit to lesions, we explored the
possibility that Dab2 could regulate EAE disease patho-
genesis by altering microglial/macrophage activation. In
EAE, activated microglia/macrophages secrete a wide
variety of factors including inflammatory cytokines, re-
active oxygen species and trophic factors which contrib-
ute to disease pathogenesis [19,20]. We performed a
targeted quantitative PCR analysis of IFNγ, IL-1β, TGFβ,
TNFα and iNOS gene expression in Dab2 wild-type and
Dab2-deficient mice in EAE spinal cord tissue harvested
at day 18. Using multivariable linear regression analysis,
we found that dab2 gene expression was positively cor-
related with iNOS (adjusted r2=0.65, p=0.003; Figure 5a)
and IL-1β (adjusted r2 = 0.45, p=0.015; Figure 5b) gene
expression independent of disease grade, whereas other
tested gene expression profiles were not correlated with
Dab2 levels when adjusted for grade. These results
strongly suggest that Dab2 could worsen EAE lesion
evolution by altering microglial/macrophage activation
through the regulation of iNOS and IL-1β signalling
pathways.
Biochemical responses to inflammatory stimuli are altered
in Dab2-deficient macrophages
To examine whether Dab2-deficient macrophages have
altered responses to pro-inflammatory stimuli, we treated
bone marrow macrophages (BMM) derived from Dab2
heterozygote and Dab2 wild-type mice with 1 μg/mL
lipopolysaccharide (LPS) or with PBS. Three independ-
ent qPCR experiments showed that Dab2 heterozy-
gote BMM expressed between 35 and 300 fold less
iNOS six hours post LPS stimulation than wild-type













































































































































Figure 3 Dab2 deletion ameliorates EAE disease severity. a/b: EAE clinical scores of MOG-induced C57B/6 wild-type, Dab2 heterozygote and
Dab2 knockout mice. a: Mice heterozygous for Dab2 have significantly repressed EAE disease scores from 14 days post-EAE induction (Mann–
Whitney rank sum test; *p<0.05, **p<0.01, ***p<0.001) b: Dab2 knockout mice have significantly repressed EAE disease scores from 12 days post-
EAE induction (Mann–Whitney rank sum test; *p<0.05, **p<0.01) c/d: Kaplan-Meier survival curves for wild-type, Dab2 heterozygote and Dab2
knockout mice. c: Figure shows that one hundred percent Dab2 heterozygote mice survived the EAE insult relative to eighty-one percent of wild-
type mice (Chi-Square test, p<0.01). d: Figure shows that ninety-six percent of Dab2 knockout mice survived the EAE insult realtive to sixty-seven
percent of wild-type mice (Chi-Square test, p<0.05). e/f: Serum phosphorylated neurofilament heavy chain (pNF-H) ELISA measure of axonal
injury. e: Figure shows that mice heterozygous for Dab2 have a significantly lower concentration of pNF-H in their serum than wild-type mice
(Two-tailed Student’s t-test p<0.01). f: Figure shows that Dab2 knockout mice have significantly less pNF-H in their serum than wild-type mice
(Two-tailed Student’s t-test, p<0.01).
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mental conditions. These results support the hypothesis
that dab2 expression by cells of the macrophage/microglial
lineage is associated with the production of nitric oxide
and provides a putative mechanism through which Dab2
expression could regulate axonal injury in EAE.
Dab2 Responses to stimulation by exogenous cytokines
in vitro
Using a candidate approach, we aimed to identify factors
that could induce dab2 and Dab2 expression. We testedthree candidate molecules reported to regulate Dab2 ex-
pression in various cell types in vitro including TGFβ1
[21,22], all-trans retinoic acid [23,24] and IFNγ [14]. We
additionally looked at dab2 expression in response to
the pro-inflammatory mediator lipopolysaccharide (LPS).
To identify putative modulators of dab2 and Dab2, we
performed in vitro analyses in primary microglia derived
from early post-natal rats. We found that dab2 expres-
sion was in fact diminished in response to all-trans ret-
inoic acid and TGFβ1 treatment. Triplicate experiments





























































Figure 4 Histological analysis of the lumbar expansion in Dab2wt/wt, Dab2wt/ko and Dab2ko/ko mice subjected to EAE. Representative
sections of the lumbar expansion of the spinal cord of a: a wild-type mouse subjected to EAE b: a Dab2 heterozygote mouse subjected to EAE c:
a Dab2 knockout mouse subjected to EAE. a/b/c: Orange lines outline immune infiltrates. Scale bar represents 500μm d: Analysis of average
number of immune lesions in the spinal cords of Dab2 heterozygous and knockout mice relative to wild-type controls reveals that mice
heterozygous for Dab2 and knockout for Dab2 have a similar number of lesions to wild-type mice (p>0.05) e: Analysis of average infiltrate area
reveals that the size of immune infiltrates found in the lumbar expansion of Dab2 heterozygous mice and Dab2 knockout mice is significantly
smaller than those found in the lumbar expansion of wild-type mice (***p<0.001) Similarly, the average size of immune infiltrates in the spinal
cords of Dab2 knockout mice is significantly smaller those found in Dab2 heterozygous mice (*p<0.05). f: Cell densitometry analysis within the
core of EAE lesions reveals that there are no significant differences between the proportional composition of various glial cell types within lesions
in wild-type and Dab2 heterozygous mice, however, total cell numbers per lesion are significantly less in Dab2 heterozygous and knockout
lesions (**p<0.01). Average ± SEM; One-Way ANOVA, Tukey’s post-hoc test; n ≥ 4 mice/genotype for all above analyses.
ba
Figure 5 qPCR quantification of gene expression in the lumbar expansion of spinal cords of Dab2wt/wt mice (n=15) in acute EAE.
Multivariate linear regression analysis reveals that Dab2 gene expression is positively correlated with a: iNOS gene expression (adjusted r2=0.65,
p=0.003) and b: IL-1β gene expression (adjusted r2=0.45, p=0.015) when controlling for disease grade 18 days post-EAE induction.
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Figure 6 Characterization of Dab2 expression within MS
lesions. Immunohistochemical staining of an early acitve lesion
(biopsy) and a chronic active lesion. a/b: Luxol Fast Blue/Periodic
Acid Schiff stain showing regions of demyelination (pink). c/d:
Staining for the macrophage/microglial marker CD68 (brown)
showing large numbers of macrophages throughtout both lesion
types. e/f: Dab2 staining in the early acitve and chronic active lesion.
e: Dab2 staining can be seen throughout the early active lesion
expressed by cells of a macrophage morphology. f: Very little
perivenular Dab2 staining (arrows) can be found in the chronic
active lesion.
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(0.46 ± 0.09, p = 0.002) and 24 hours (0.45 ± 0.03,
p = 0.004) post-treatment relative to control expression
(1.02 ± 0.08). In addition we found that TNFα expression
was similarly diminished in response to all-trans retinoic
acid (Additional file 5: Figure S5a). Similarly, dab2 gene
expression levels were reduced at 6 hours (0.46 ± 0.08, p =
0.014) and at 24 hours (0.37 ± 0.03, p = 0.004) relative to
control expression (1.03 ± 0.08) in response to 10 ng/ml
TGFβ1 (Additional file 5: Figure S5b). Again, we found this
to be a likely non-specific anti-inflammatory response with
TNFα expression levels also reduced in the experiment. In
addition, we found that Dab2 was phosphorylated in
response to TGFβ1 treatment. Phosphorylation of Ser24
was rapid, but transient, lasting less than 30 minutes
(Additional file 5: Figure S5c). We were unable to find any
cytokines that induced dab2 gene expression, including
IFNγ and LPS (data not shown).
Dab2 Is highly expressed in acutely demyelinating human
MS lesions
Having demonstrated that, in EAE spinal cord Dab2 is
expressed predominantly by macrophages/microglia and
astrocytes, we sought to characterise Dab2 expression
within MS lesions (Figure 6). Disabled-2 expression was
assessed in early active (acute), late active (acute), or
chronic active lesions, classified according to previously
described criteria [25]. Acute active lesions were defined
by the presence of macrophages with MOG-positive
myelin debris (early active) or PAS-positive but MOG-
negative myelin debris (late active), (Figure 6c & 6d).
Chronic active lesions had a rim of macrophages/
microglia surrounding a hypocellular demyelinated lesional
core.
Immunohistochemical analysis revealed that Dab2
was very highly expressed within early active lesions
(Figure 6e) and coincided with intense APP staining
(Additional file 6: Figure S6), a marker of axonal injury
(Table 1). Examination of a late acute lesion revealed a
marked decrease in Dab2 staining, as well as a decrease
in the number of APP-positive elements. Occasional
Dab2-positive cells were found within chronic active le-
sions (Figure 6f ), more commonly in the venous spaces
and only rarely in the parenchyma (Table 1). Morpho-
logically, the dab2-expressing cells were characterised as
macrophages or microglia by an experienced neuropath-
ologist (TK).
Discussion
In the present study, we have demonstrated that dab2
expression in the spinal cord is induced by EAE and
positively correlated with EAE disease severity during
the acute disease phase. Expression of the protein in
this context is restricted to macrophages/microglia,astrocytes and oligodendrocytes, particularly perilesional
and lesional microglia/macrophages and astrocytes. A
recent study has similarly demonstrated that Dab2 is
expressed by astrocytes and macrophages in the rat EAE
model [26].
We have shown that mice with a heterozygous or
homozygous deletion of dab2 exhibited lower disease se-
verity and higher survival rates, less axonal injury and
smaller neuroinflammatory lesions when subjected to
EAE compared to wild-type littermate controls. The
level of induced dab2 gene expression was positively
correlated with the gene expression of iNOS and IL-1β,
markers of microglial/macrophage activation [19], after
adjusting for disease severity. A direct link between
dab2 induction and expression of iNOS was further
supported by our in vitro analyses that showed that
dab2-deficient macrophages expressed lower levels of
iNOS relative to wild-type controls when challenged
with LPS, activating TOLL-like receptors. Therefore,
these results suggest that Dab2 upregulation is asso-
ciated with a pro-inflammatory M1 macrophage/microglial
phenotype.
Table 1 Immunoreactivity in human MS Lesions
Marker (μ ± SD)








129.9 ± 25.5 164.1 ±28.3 24.2 ± 5.8
Early active –
biopsy 2
86.4 ± 7.7 96.9 ± 12.3 23 ± 4.2
Late active –
biopsy 3
10.1 ± 4.1 96.9 ± 19.7 4.9 ± 3.6
Chronic active –
autopsy 1
0.64 ± 1.0 58.7 ± 15.8 4.2 ± 1.9
Chronic active –
autopsy 2
0.20 ± 0.42 14.0 ± 4.1 2.6 ± 0.97
Chronic active –
autopsy 3
0.10 ± 0.32 12.8 ± 4.1 1.8 ± 1.2
Table 1 summarizes Dab2, CD68 and APP positive cell density in serial sections
of lesions obtained from biopsy or autopsy specimens.
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glial/macrophage activation, and thereby lesion expan-
sion, via increased expression of nitric oxide (NO) and,
potentially, IL-1β in the context of murine EAE. These
findings are particularly interesting as nitric oxide has
been directly implicated in oligodendrocyte cell death
[27,28] and has previously been reported to play a role
in MS lesion pathogenesis [29-32]. Specifically, nitric
oxide and iNOS producing microglia/macrophages and
astrocytes are present in active human MS lesions, but
are rare in chronic lesions and absent in normal tissue,
supporting the notion that macrophage and astrocyte-
derived nitric oxide production also exacerbate MS
lesion-associated tissue injury [31,33-35].
In our hands, the C57B/6 MOG35-55 EAE model is a
model of axonal injury and inflammation, with little de-
myelination or oligodendrocyte death [36]. Here we re-
port that axonal injury was reduced in dab2-deficient
mice subjected to EAE. Multiple mechanisms could ac-
count for this observation. Firstly, it is believed that re-
active oxygen species produced by microglia induce
mitochondrial dysfunction, resulting in energy failure
and axonal injury in MS [37]. Therefore, it is possible
that dab2-deficient mice that produced less iNOS expe-
rienced less mitochondrial dysfunction and thereby had
a relative preservation of axons relative to their wild-
type littermates subjected to EAE. Secondly, dab2-defi-
cient EAE mice exhibited smaller inflammatory cord
infiltrates and thus contained fewer total microglia and
macrophages within their spinal cords as compared with
their wild-type littermates. Past in vitro studies have dem-
onstrated that microglia/macrophage-mediated axonal
transection occurs via a contact-dependent mechanism
[27]. Therefore, it is possible that, in dab2-deficient mice,
axonal transection was reduced due to fewer numbers of
activated microglia making contact with axonal segments.This paper presents evidence that Dab2-dependent
microglial/macrophage responses worsen inflammatory
tissue damage in EAE. As we have also shown high
levels of Dab2 protein expression in cells with a macro-
phage morphology in early acute MS lesions, this finding
could be of relevance to human MS. We have also dem-
onstrated that MS lesional Dab2 expression markedly
decreases within late active lesions and that it is almost
absent in chronic active lesions. Additionally, we showed
that high levels of Dab2 expression were associated with
marked axonal injury in MS, again consistent with our
acute EAE data that demonstrated that dab2-deficient
mice had significantly less axonal injury than their wild-
type littermates when subjected to EAE. Haider and col-
leagues recently established that oxidative damage is
most profound in active MS lesions in which there is a
high density of macrophages/microglia [38]. Given that
we found Dab2 expression to be greatest in early acute
lesions, and given that we have found an association be-
tween dab2 expression and iNOS expression, it is pos-
sible that dab2 up-regulation could lead to increases in
the expression of reactive oxygen species, thus contrib-
uting to oxidative damage caused to axons, myelin and
oligodendrocytes in these earliest lesions.
During the course of this study, we aimed to identify
signals responsible for the up-regulation of dab2 expres-
sion. However, candidates tested did not result in
increases in dab2 expression. Therefore, we can con-
clude that dab2 expression is not directly mediated via
Toll-like receptor signalling, nor through IFNγ signalling
pathways. We did find, however, that both TGFβ1 and
all-trans retinoic acid were responsible for the down-
regulation of dab2 in macrophages/microglia, although
this was not a dab2-specific response, but rather part of
a broader anti-inflammatory response, as previously
described [39-42].
In addition to regulating pro-inflammatory biochem-
ical pathways, a further possibility is that Dab2 may
regulate cell migration in the context of EAE, as
reported in other experimental paradigms [8,14]. Al-
though we did not find any evidence of a selective
macrophage/microglial recruitment deficit to lesions in
Dab2-deficient mice, we found that Dab2-deficient EAE
tissue was less cell-dense than wild-type EAE tissue. The
lower overall density of macrophages/microglia in Dab2-
deficient tissue could partially explain the effect of
Dab2-deficiency on EAE severity. Future studies will
benefit from a myeloid-lineage specific Dab2-knockout
mouse model to further interrogate the role of Dab2 in
these cells in EAE.
It has been reported that dab2 is expressed in periph-
eral T-lymphocytes, however its expression is restricted
to a FOXP3-positive T-regulatory cell population [22].
However, to exclude the possibility that EAE disease
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aberrant T-cell priming, activation or regulation, we
performed passive transfer EAE experiments, trans-
planting T-cells from Dab2-deficient mice into wild-type
mice. We were able to induce disease in all eight wild-
type recipient mice demonstrating that the EAE pheno-
type observed in Dab2-deficient mice was not mediated
by altered signalling in T-lymphocytes. Additionally, we
did not find any co-localisation between Dab2 and CD3
antigens within T-lymphocytes that had migrated into
CNS lesions in wild-type mice subjected to EAE.
In this study, we did not probe the potential role of
Dab2 in astrocyte or oligodendrocyte biology. It is pos-
sible that Dab2 mediates responses to inflammatory
stimuli in these cell types, however this requires further
investigation.
Conclusions
Collectively, the data presented in this paper demon-
strate that Dab2 is up-regulated in macrophages/microglia
in acute EAE lesions and in early acute MS lesions. In
EAE, we have shown that this endogenous upregulation is
harmful, exacerbating axonal injury and worsening disease
severity and disease-associated mortality. The molecule
could be a future therapeutic drug target in MS, but no
Dab2-specific inhibitors are known at present.
Methods
Ethics approvals
All animal experimentation was conducted according to
National Health and Medical Research Council guide-
lines (Australia) and with approval from the Howard
Florey Institute animal ethics committee.
Human histological studies were conducted in the
laboratory of co-author T. Kuhlmann. All human mater-
ial was sourced from the Neuropathology archives at the
University of Muenster. Biopsies were conducted to
exclude malignancy, and none of the authors had any
part in the clinical management of the patients. Evalu-
ation of neuropathological material was conducted using
codified samples and conducted under the governance
and with ethics approvals of the University of Muenster.
Animals and reagents
C57B/6 and SJL/J mice were obtained from the Animal
Resource Centre (Canning Vale, Western Australia,
Australia). The (129sv/C57B/6) Dab2 loxP flanked strain
(Dab2fl/fl) was a kind gift from Dr. Johnathan Cooper of
the Fred Hutchinson Cancer Research Centre (Seattle,
WA) [8]. These mice were backcrossed for 12 genera-
tions to generate a Dab2 loxP flanked strain on a C57B/
6 background. The Meox2-Cre line was obtained from
The Jackson Laboratory (Bar Harbor, Maine) on a mixed
background (129sv/C57B/6 backcrossed onto a C57B/6background for six generations). These mice were fur-
ther backcrossed on to a C57B/6 background for 8 gen-
erations. Dab2fl/fl mice were crossed to Meox2-cre mice
to generate animals in which Dab2 was deleted from the
embryo, whilst preserving Dab2 expression within extra-
embryonic tissue (Dab2 wild-type, Dab2 heterozygote,
Dab2 knockout mice).
All chemicals were obtained from Sigma-Aldrich (St.
Louis, MO) unless otherwise specified. All cell culture
plasticware was purchased from Nalgene Nunc Inter-
national (Rochester, NY). All cell culture media and re-
agents were purchased from Invitrogen (Carlsbad, CA).
All secondary antibodies were purchased from Jackson
ImmunoResearch Laboratories (West Grove, PA) unless
otherwise noted.
Experimental autoimmune encephalomyelitis (EAE)
induction
EAE was induced in 8–12 week old male and female
mice by subcutaneous injection into the flanks and base
of tail of 125μg of MOG35-55 (MEVGWYRSPFSRVV
HLYRNGK) or PLP139-151 (HSLGKWLGHPDKF) (Auspep,
Australia) emulsified in Complete Freund’s Adjuvant
containing 4mg/ml Mycobacterium tuberculosis H37Ra
(Difco, Detroit, MI). Mice also received an intraperitoneal
(i.p) injection of 400 ng pertussis toxin (List Biological,
Campbell, CA) on days 0 and 3 of induction. Assessments
of EAE severity were performed daily according to a
9-point paraplegia scale with 0.5-point increments [43,44].
Mice that reached grade 3.5 were killed in accordance
with ethics committee requirements. EAE cohort 1 com-
prised Dab2wt/wt (n=32) and Dab2wt/ko (n=37) mice.
EAE cohort 2 comprised Dab2wt/wt (n=27) and Dab2ko/
ko (n=16) mice. Fewer Dab2ko/ko mouse numbers were
available due to the relative difficulty in deriving this
genotype.
Unless specified otherwise, all mouse tissue was de-
rived from mice 18 days post-EAE induction.
Non-parametric statistical analyses were used to de-
termine statistical significance of biological phenotypes
seen in EAE experiments. The Mann–Whitney Rank
Sum Test was used to compare between 2 groups
(Dab2wt/wt versus Dab2wt/ko or Dab2wt/wt versus
Dab2ko/ko) of EAE challenged animals. Survival was
analysed using Kaplan-Meier survival curves followed by
Log Rank test statistical analyses.
Microarray analysis of gene expression
Microarray studies were performed on whole spinal tis-
sue from 8 week old SJL/J mice subjected to EAE, and
from age and gender matched healthy control mice
killed on the same day. All EAE mice were killed at a
disease level of severe hindlimb paraparesis or complete
hindlimb paraplegia (EAE grade 2.5-3.0). Mice were
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kg i.p) and intracardially perfused with 20mls 0.1 M PBS.
The spinal cords were removed and immediately snap
frozen in liquid nitrogen, and then stored at −80°C until
use. RNA was extracted using an RNeasy mini kit
(QIAGEN Pty Ltd. Vic, AUS) as per manufacturer’s in-
structions. Samples were incubated with 600 μl buffer
RLT and homogenized using a Dounce homogenizer.
The total RNA from spinal cords of two animals were
pooled prior to the labeling reaction. A total of three
healthy control pair samples (6 mice, n = 3) were com-
pared with a total of five EAE pair samples (10 mice, n =
5). The RNA was then hybridized onto the murine MG
U74Av2 microarray, Affymetrix®, Santa Clara CA, fol-
lowing manufactures instructions.
Expression data was analysed using Partek® genomics
suite, Missouri, USA. Affymetrix® annotation library
MG_U74Av2.na31.annot.csv was used and Data was
normalized using RMA (Bolstad et al. 2003) and quantile
normalization and adjusted for GC content. Expression
values were log transformed using base2 prior to differ-
ential expression analysis using a 2 way ANOVA on
treatment and batch. Cel files and normalized expression
data have been deposited at the Gene Expression Omni-
bus (GSE44989).
Adoptive transfer EAE
Adoptive transfer EAE was performed as previously de-
scribed [45]. Briefly, active MOG35-55 EAE was induced
in 8 to 12 week old male and female Dab2 knockout
(n=5) and Dab2 heterozygous (n=3) donor mice. On day
10 post-immunization, T-lymphocytes were isolated
from the draining lymph nodes and spleens of these
mice. Cells were cultured in complete DMEM con-
taining 50 ug of MOG35-55 peptide and 20 ng of IL-2, for
48 h at 37C in a 5% CO2 incubator. After this time, the
non-adherent T-lymphocytes were collected, washed
twice with PBS containing 0.5% FBS, and injected into
C57B/6 wild-type recipient mice at a concentration of
2x106 cells in 0.1 ml PBS, i.p, per mouse (transfer ratio
was approximately 1 donor to 1 recipient mouse). On
the same day, recipient mice were injected with 300 ng
pertussis toxin i.p. on the opposite side to the site of T-
lymphocyte cell injection. Assessments of disease sever-
ity were performed daily for 22 days as described above.
Histology and immunohistochemistry
Mouse
Mice were anesthetized and intracardially perfused with
MT-PBS followed by 4% paraformaldehyde. The lumbar
expansions of spinal cords were isolated and equilibrated
in 20% sucrose prior to embedding in OCT. Spinal cords
were then sectioned at 10 μm intervals and collected
onto chrom-alum-coated slides.To detect murine Dab2, sections were rehydrated in
MT-PBS and post-fixed in ice-cold acetone/methanol
50%/50% v/v solution for two minutes. Sections were
washed 3x in MT-PBS, and blocked in 10% (v/v) normal
goat serum (NGS) in MT-PBS with 0.5% BSA and 0.3%
(v/v) TritonX-100 for 1hr at RT. Sections were labelled
with rabbit anti-Dab2 (1:100; Santa Cruz Biochemicals,
Santa Cruz, CA) alone, or in combination with rabbit
anti-NG2 (1:200; Chemicon, Billerica, MA), mouse anti-
GFAP (1:500; Chemicon), PE-CD11b antibody (2 μg/ml;
CALTAG, Carlsbad, CA), or IgG2b-PE isotype control
(2 μg/ml, BD, Franklin Lakes, NJ), rabbit anti-CD3 (1:100,
DAKO, Glostrup, Denmark), mouse anti-NeuN (1:500,
Chemicon) for 3 hrs at RT. Appropriate fluorescently-
labelled secondary antibodies against host species were
used at a dilution of 1:500 for 30 minutes at RT. Images
were acquired by confocal microscopy (Zeiss LSM5
PASCAL).
Human biopsy and autopsy specimens
This study was approved by the ethics committee of the
University of Münster.
Classification of multiple sclerosis lesions
All lesions fulfilled the generally accepted criteria for the
diagnosis of multiple sclerosis [46,47]. Demyelinating ac-
tivity was classified as described in detail earlier [48].
Biopsy specimens were fixed in 4% paraformaldehyde
and embedded in paraffin. Autopsy material was gene-
rally fixed in 10% formalin and tissue blocks containing
lesions were embedded in paraffin. Biopsy and autopsy
tissues were cut in 4 m thick sections and stained with
haematoxylin and eosin, Luxol-fast blue and Bielschowsky’s
silver impregnation for lesion classification.
After deparaffinization, antigen retrieval was per-
formed using a slide steamer for 35 minutes with a solu-
tion of Tris-EDTA (pH 9.0). After cooling slides on ice
and two water rinses, intrinsic peroxidase activity was
blocked by incubation with 5% H2O2 in PBS for 20 min.
Non-specific antibody binding was inhibited with 10%
FCS in PBS for 20 min. For the Dab2 stain, this was
followed by incubation with mouse anti-Dab2 IgG1,
(BD, 610465) at 1/100, in the same block for 12 hours at
4 degrees. The stain was developed using avidin-biotin
immunohistochemistry with a secondary anti-mouse
biotinylated Ab and the Vector ABC kit according to the
manufacturer’s instructions, followed by the DAB re-
action, which was terminated after 8 minutes. Controls
omitting the primary Ab showed no staining. The slides
were briefly dipped in haematoxylin solution for counter-
staining before mounting.
For the APP/CD68 double stain, the sections were first
incubated with mouse anti-human APP Ab (Chemicon
MAB348) at 1/2000 in block at 4 degrees for 12 hrs,
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kaline phosphatase, which was visualised using NBT/
BCIP. This was followed by incubation with mouse anti-
human CD68 (DAKO, M0876) at 1/100 in block for
12 hrs at 4 degrees followed by secondary goat anti-
mouse IgG3-HRP (ABD serotec, STAR136P) at 1/200
for one hour, followed by DAB development and brief
haematoxylin couterstain followed by mounting.
Morphometry for human sections
Cell numbers and APP positive elements are expressed
as an average number per 10 000 mm2 using 40x magni-
fication. Averages were obtained by counting at least 6,
and if possible, 10 standardised fields of view per lesion
of 10 000 mm2 each defined by an ocular morphometric
grid as previously described [25]. Fields for quantitating
acute lesions were selected from within the heavily
macrophage-infiltrated areas of the biopsies and, for the
chronic active lesions, the edge of the lesions containing
macrophages/microglia was selected.
Quantitative PCR
cDNA was generated from 1μg of RNA using Taqman Re-
verse Transcription reagents (Applied Biosystems, Foster
City, CA) according to manufacturer’s instructions. Quan-
titative PCR (qPCR) reactions were performed using
Cybergreen PCR mastermix (Applied Biosystems) on a
7500 Fast Real Time PCR System (Applied Biosystems)
using the comparative Ct method (Livak & Schmittgen,
2001). qPCR primers were designed using Primer Express
3.0 (Applied Biosystems). Primer sequences were as
follows: mouse 18S, forward 5′CGGCTACCACATCCA
AGGAA3′, reverse 5′GCTGGAATTACCGCGGCT3′;
mouse Dab2 (exon 3 to detect p96 and p67) forward 5′
TGTTGGCCAGGTTCAAAGGT3′, reverse 5′GCACAT
CATCAATACCGATTAGCT3′; mouse IFNγ forward 5′
TTGGCTTTGCAGCTCTTCCT3′, reverse 5′TGACTG
TGCCGTGGCAGTA3′; mouse iNOS forward 5′GGAT
CTTCCCAGGCAACCA3′, reverse 5′AATCCACAACT
CGCTCCAAGATT3′. qPCR Ct values were normalised
to 18S [49]. A dissociation step was performed to ensure
that the signal produced was specific to the generation of
a PCR product, and not due to primer dimerization.
Statistical significance was tested using the Spearman’s
correlation co-efficient to analyse the correlation bet-
ween EAE grade and fold increase of dab2. One-Way
ANOVA with a 95% confidence interval, followed by
Tukey’s post hoc comparison was used to test the expres-
sion of Dab2 at varying disease grades. Multivariate
linear regression analysis was used to analyse the correl-
ation between Dab2 expression and the expression of
pro-inflammatory mediators in the spinal cords of Dab2
wild-type and Dab2 heterozygous mice subjected to EAE
whilst controlling for EAE score.Western blotting
Protein lysates (100μg) together with pre-stained protein
standards (Bio-Rad, Hercules, CA) were run on 8%
Novex Tris-Glycine gels (Invitrogen). Proteins were
transferred onto PVDF membranes (Pall Corporation,
Port Washington, NY), blocked with 5% skim milk and
probed with mouse anti-Dab2 (1:500; BD) at 4°C over-
night (O/N). Membranes were washed 4x, followed by
incubation with a goat-anti mouse HRP-conjugated sec-
ondary antibody (Upstate, Billerica, MA) for 1 hour at RT.
Membranes were washed 6x prior to exposure to an en-
hanced chemiluminescence detection system (Amersham,
Fairfield, CT). Signal detection was performed on a
FUJIFILM LAS3000 imaging system, using LAS-3000 im-
aging software.
Histological analysis of EAE disease severity
Inflammation analyses were performed by examining at
least four, 10 μm sections per animal taken 50 μm apart
to cover a minimum cross-sectional area of 200 μm of
the lumber expansion of the spinal cord. Spinal cord
area (μm2), the number of discrete immune infiltrates
per spinal cord section and the size of each individual
infiltrate (μm2) were analysed by an experimenter
blinded to the genotype of the mice. Lesions were de-
fined as areas of dense accumulation of Hoechst-positive
nuclei both within the white and grey matter. All results
are presented as average ± SEM. Statistical significance
was tested using One-Way ANOVA with a 95% confi-
dence interval, followed by Tukey’s post hoc test.
Lesion composition analysis was performed on three
lesions per transverse section per mouse within the
lumbar expansion of the spinal cord. To detect cell-
specific markers, 10μm sections were rehydrated in MT-
PBS and then blocked in 10% (v/v) NGS in MT-PBS
with 0.5% BSA and 0.3% (v/v) TritonX-100 for 1hr at
RT. Serial sections were labelled with primary antibodies
directed against the microglial marker ionized calcium-
binding adaptor molecule-1 (Iba1, 1:1,000; Wako Pure
Chemicals, Tokyo, Japan); the astrocytic marker GFAP
(1:500; Chemicon); and the oligodendrocyte precursor
cell marker NG2 (1:200; Chemicon) in blocking solution
at 4°C O/N. Appropriate fluorescently-labelled second-
ary antibodies against host species were used at a dilu-
tion of 1:500 for 1 hour at RT. Sections were also
labelled with Hoescht 33342 (1:5,000; Invitrogen) for nu-
cleus detection. Images were obtained using an upright
microscope (Zeiss Axioplan 2) at x40 magnification. Im-
ages were opened in Adobe Photoshop CS3 and cropped
such that the region of interest for each lesion was con-
sistent between cell-specific stains. Regions of interest
contained only cells constituting the core of the lesion.
Counts of immuno-positive cells with nuclei were deter-
mined for each image and expressed as cells/mm2. All
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genotype of the animal. All results are presented as aver-
age ± SEM. Statistical significance was tested using One-
Way ANOVA with a 95% confidence interval, followed
by Tukey’s post hoc test.
pNF-H ELISA
Phosphorylated neurofilament heavy chain (pNF-H)
enzyme-linked immuno-sorbent assay (ELISA) analyses
were performed using a chicken anti-pNF-H antibody
(EnCor Biotechnology, Gainesville, FL) as previously de-
scribed in detail [16]. Statistical significance was tested
using a Two-tailed Student’s t-test with a 95% confidence
interval.
Isolation and culture of mouse microglia
Primary mixed glial cell cultures were prepared from the
brains of P1.5 C57B/6, CD11b-cre Dab2 knockout or
Meox2-cre Dab2 knockout mouse pups by exploiting
differential adhesion to plastic. In brief, mice were anes-
thetized with isofluorane, decapitated and brains removed
to HBSS (Invitrogen) containing 1mM sodium pyruvate,
10mM HEPES, 0.14% glucose, 0.3% BSA and 1.16mM
MgSO4. The meninges and choroid plexus were removed;
the whole brain was minced and then digested in 0.015%
trypsin (w/v) for 15 minutes. The trypsin reaction was
stopped with the addition of 0.05% trypsin inhibitor (w/v).
Cells were briefly centrifuged and resuspended in DMEM
containing 1 mM sodium pyruvate, 0.05% insulin and 10%
foetal calf serum (FCS). Cells were triturated to a single
cell suspension, plated in PDL-coated 75 cm2 tissue cul-
ture flasks and cultured at 37°C/5% CO2. Culture media
was changed on days 1 and 7 of culture. Microglia were
isolated on day 13 by gentle percussion and collected
together with the glial conditioned media (GCM). Cells
were briefly centrifuged and plated on 6cm2 tissue culture
dishes for 24 h in 50% GCM/50% Macrophage-SFM
(Invitrogen), 0.5% FCS to allow cells to quiesce and ramify
before experimentation. After 24 h, media was replaced
with 100% Macrophage-SFM/0.5% FCS for 16 hours and
cultured at 37°C/5% CO2. For assessment of microglial
activation cells were either treated with D-PBS (control)
or 1 μg/ml LPS for 24 hours prior to RNA isolation.
Isolation and culture of mouse bone marrow
macrophages
Mice were given a lethal dose of sodium pentobarbital
(100 mg/kg i.p), and immediately following death, the
femur and tibia were excised with fine scissors. Using a
23G needle and syringe filled with DMEM (Gibco), the
bone marrow was flushed into a tube containing 40 ml
of cold DMEM. Cells were pelleted by centrifugation at
350 x g for 5 min, and then resuspended at 1x106 cells/
ml in macrophage medium (DMEM, 10% FCS, CSF-1,100 U/ml penicillin, 100 ug/ml streptomycin, 2 mM
GlutaMax-1) and seeded onto a non-coated T75 tissue
culture flasks for 3 days in a 5% CO2 incubator at 37°C.
After 3 days, non-adherent cells were collected and
centrifuged at 350xg for 7 min. The cells were then
resuspended in macrophage media and plated at a dens-
ity of 1.5 million cells/per well onto non-coated 6-well
plates (IWAKI). To promote macrophage differentiation,
MCSF (2.5 ng/ml) was also added to the media, and the
cells were incubated for 4 days. The day before experi-
ments (day 8 following isolation), a full media change
was performed (including the addition of MCSF), and
cells were left to settle overnight.Statistical analyses
Individual statistical tests were performed as described in
relevant sections with a minimum alpha level of 0.8. All
reported p values are two-tailed and for each analysis
p<0.05 was considered significant. Statistical analyses were
performed using SigmaStat 2.03 (Systat Software Inc, San
Jose, CA). Multivariable linear regression analyses ad-
justing for EAE disease severity were performed using
Stata version 12.0 (StataCorp College Station, Texas).Additional files
Additional file 1: Figure S1. Characterization of Dab2 expression by
oligodendroglia within the EAE spinal cord. Immunofluorescence staining
for Dab2 in the EAE grade 3.0 spinal cord of a C57/B6 wild-type mouse.
Representative confocal images show a: co-localisation of Dab2 within a
subpopulation of PLPdsRed-expressing oligodendrocytes in an
inflammatory lesion (arrows). b: co-localisation of Dab2 within a
subpopulation of NG2-positive oligodendrocyte progenitor cells (arrow).
Scale bars represent 50 μm.
Additional file 2: Figure S2. In vitro expression of Dab2 in primary glia.
a: Immunoprecipitation-Western blot analysis shows that oligodendrocyte
progenitor cells,mature oligodendrocytes, astrocytes and microglia
express both the p96 and p67 isoforms of Dab2. The p96 isoform is
expressed more highly in astrocytes, whereas the p67 isoform is more
highly expressed in microglia. b: dab2 mRNA is expressed by cultured
primary glial cells, with the highest levels in microglia, with diminishing
expression by astrocytes, oligodendrocyte precursors and mature
oligodendrocytes. ttest *p<0.05, **p<0.01.
Additional file 3: Figure S3. Histological analysis of NAWM the lumbar
expansion in Dab2wt/wt, Dab2wt/ko and mice subjected to EAE and in
the dorsal column of healthy mice. A: Tissue was derived from mice at 18
days post-EAE induction. Cell densitometry analysis within normal-
appearing white matter (NAWM) reveals that there are no significant
differences between the proportions of Iba1+ microglia, GFAP+
astrocytes, and NG2+ oligodendrocyte progenitors in wild-type and Dab2
heterozygous mice within these regions. Total cell numbers within the
NAWM of Dab2 heterozygous mice, however, are significantly fewer than
in the NAWM of wild-type littermates (Average ± SEM; two-tailed
student’s t-test, p<0.01). B: Analysis of cell densities within the dorsal
column of Dab2 wild-type, heterozygote and knock-out mice reveals that
there are no significant differences in the densities of GSTpipositive
oligodendrocytes, Iba1-positive microglia, GFAP-positive astrocytes, NG-2
progenitors nor in total cell densities (n=3,4,3 animals/genotype
respectively; Average ± SEM; One- Way ANOVA, p>0.05) 3.
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wild-type mice T-cells derived from EAE-induced Dab2-deficient mice
were able to passively transfer disease in C57B/6 wildtype mice. Disease
was induced in 5/5 wild-type recipients after transfer of T-cells from Dab2
knockout mice, and in 3/3 wild-type recipients after transfer of T-cells
from Dab2 heterozygote mice. There were no significant differences
between groups (Mann-Whitney rank sum test, p>0.05 at all time points).
Additional file 5: Figure S5. In vitro modulation of Dab2 a: All-trans-
Retinoic Acid has a potent anti-inflammatory effect on gene expression
profiles within primary microglia. dab2 and TNFα gene expression are
significantly down-regulated at 6 and 24 hours post-treatment with 1 μM
Retinoic Acid (**p<0.01; ***p<0.001). b: TGFβ1 (10ng/ml) down-regulates
dab2 and TNFα gene expression in primary microglia (*p<0.05; **p<0.01).
a/b: n = 3 expts; Average ± SEM; One-Way ANOVA) c: Western blot probe
for phosphorylated Dab2 p96 isoform and bactin loading control. Dab2
expressed by primary microglia is rapidly but transiently phosphorylated
in response to TGFβ1. Phosphorylated Dab2 is present within 5 minutes
of treatment, but no longer observed 30 minutes after the exogenous
TGFβ1 pulse.
Additional file 6: Figure S6. APP staining in MS Lesions a/b: APP
staining for axonal injury (arrows) in the early active lesion (a: brown) and
chronic acitve lesion (b: blue, CD68 brown) shows that axonal injury is
much more pronounced in the early active lesion than in the chronic
active lesion.
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